Atyr和Athira Pharmas的短期利息暴涨,而Atara生物治疗剂则下降。 Short interest surged for Atyr and Athira Pharmas, while Atara Biotherapeutics saw a drop.
11月,Atyr Pharma和Athira Pharma的短期利息飙升,分别增长了27.1%和43.2%,而Atara生物治疗公司下降了18.4%。 In November, short interest surged for Atyr Pharma and Athira Pharma, with increases of 27.1% and 43.2% respectively, while Atara Biotherapeutics saw a 18.4% drop. Atyr Pharma的主要候选人 efzofitimod 正在临床试验肺部骨质疏松症。 Atyr Pharma's lead candidate, efzofitimod, is in clinical trials for pulmonary sarcoidosis. Athira Pharma侧重于小分子,用于治疗神经退化性疾病。 Athira Pharma focuses on small molecules to treat neurodegenerative diseases. Atara生物治疗主要产品Tab-cel的目标是Epstein-Barr病毒引起的疾病。 Atara Biotherapeutics' lead product, Tab-cel, targets Epstein-Barr virus-driven diseases.